| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Balancing efficacy and safety of JAK inhibitors in myelofibrosis
|
Passamonti, Francesco
|
|
2014
|
38 |
3 |
p. 290-291
2 p.
|
artikel
|
| 2 |
Editorial board and publication information
|
|
|
2014
|
38 |
3 |
p. CO2-
1 p.
|
artikel
|
| 3 |
Elacytarabine in relapsed/refractory acute myeloid leukaemia: An evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile
|
Knapper, Steven
|
|
2014
|
38 |
3 |
p. 346-351
6 p.
|
artikel
|
| 4 |
Electromagnetic fields at extremely low frequencies and the risk for childhood leukemia: Do we have enough information to warrant this association?
|
Valera, Elvis Terci
|
|
2014
|
38 |
3 |
p. 289-
1 p.
|
artikel
|
| 5 |
Expression and function of a novel isoform of Sox5 in malignant B cells
|
Edwards, Shanique K.E.
|
|
2014
|
38 |
3 |
p. 393-401
9 p.
|
artikel
|
| 6 |
Extramedullary chronic lymphocytic leukemia: Systematic analysis of cases reported between 1975 and 2012
|
Ratterman, Megan
|
|
2014
|
38 |
3 |
p. 299-303
5 p.
|
artikel
|
| 7 |
Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual
|
Cramer, Paula
|
|
2014
|
38 |
3 |
p. 284-285
2 p.
|
artikel
|
| 8 |
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
|
Tembhare, Prashant R.
|
|
2014
|
38 |
3 |
p. 371-376
6 p.
|
artikel
|
| 9 |
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
|
Erba, Harry P.
|
|
2014
|
38 |
3 |
p. 329-333
5 p.
|
artikel
|
| 10 |
Magnetic fields exposure and childhood leukemia risk: A meta-analysis based on 11,699 cases and 13,194 controls
|
Zhao, Longyu
|
|
2014
|
38 |
3 |
p. 269-274
6 p.
|
artikel
|
| 11 |
Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells
|
Kaczmarek, Monika Z.
|
|
2014
|
38 |
3 |
p. 377-382
6 p.
|
artikel
|
| 12 |
miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia
|
Ufkin, Melanie L.
|
|
2014
|
38 |
3 |
p. 402-410
9 p.
|
artikel
|
| 13 |
Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease – Systematic review and meta-analysis
|
Ram, Ron
|
|
2014
|
38 |
3 |
p. 352-360
9 p.
|
artikel
|
| 14 |
Nilotinib 300mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
|
O’Dwyer, Michael E.
|
|
2014
|
38 |
3 |
p. 310-315
6 p.
|
artikel
|
| 15 |
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
|
Verstovsek, Srdan
|
|
2014
|
38 |
3 |
p. 316-322
7 p.
|
artikel
|
| 16 |
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro
|
Dilley, Robert L.
|
|
2014
|
38 |
3 |
p. 411-417
7 p.
|
artikel
|
| 17 |
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
|
Efficace, Fabio
|
|
2014
|
38 |
3 |
p. 294-298
5 p.
|
artikel
|
| 18 |
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
|
Kraus, Marianne
|
|
2014
|
38 |
3 |
p. 383-392
10 p.
|
artikel
|
| 19 |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1
|
Tomita, Osamu
|
|
2014
|
38 |
3 |
p. 361-370
10 p.
|
artikel
|
| 20 |
The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells
|
Essig, Aitomi
|
|
2014
|
38 |
3 |
p. 340-345
6 p.
|
artikel
|
| 21 |
The challenge of the ‘C’ in CML
|
Mauro, Michael J.
|
|
2014
|
38 |
3 |
p. 286-
1 p.
|
artikel
|
| 22 |
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q—New prognostic markers are needed
|
Kuendgen, Andrea
|
|
2014
|
38 |
3 |
p. 287-288
2 p.
|
artikel
|
| 23 |
The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
|
Yan-Li, Li
|
|
2014
|
38 |
3 |
p. 323-328
6 p.
|
artikel
|
| 24 |
The prevalence and prognostic value of concomitant eosinophilia in chronic graft-versus-host disease after allogeneic stem cell transplantation
|
Mortensen, Katrine Brandt
|
|
2014
|
38 |
3 |
p. 334-339
6 p.
|
artikel
|
| 25 |
Therapy-related AML: A slip of the lip can sink a ship
|
Gale, Robert Peter
|
|
2014
|
38 |
3 |
p. 418-420
3 p.
|
artikel
|
| 26 |
The relevance of a geriatric assessment for elderly patients with a haematological malignancy – A systematic review
|
Hamaker, M.E.
|
|
2014
|
38 |
3 |
p. 275-283
9 p.
|
artikel
|
| 27 |
The role of CD81 for plasma cell dyscrasias
|
Binder, Mascha
|
|
2014
|
38 |
3 |
p. 292-293
2 p.
|
artikel
|
| 28 |
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
|
Rojas, Silvia M.
|
|
2014
|
38 |
3 |
p. 304-309
6 p.
|
artikel
|
Tijdschrift beschrijving